Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment

NCT04490915 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT04490915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04490915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
Lead sponsor
Neurocrine Biosciences
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 16, 2020
Completion date
August 31, 2027
Enrollment
182 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

congenital adrenal hyperplasia